Over 60% of pharma MSMEs yet to comply with updated manufacturing norms
Published on: June 3, 2026, 11:30 a.m. | Source: The Economic Times
Pharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shortages, funding constraints, and rising compliance costs pose challenges for smaller drug makers within the SME ecosystem..
